EUVIMEDEUVIMED entdecken
Crossref

Polyphyllin VI: A promising treatment for prostate cancer bone metastasis

Yanbin Feng, Yaomin Mo, Yang Zhang, Yilin Teng, Deshuang Xi, Junhong Zhou, Gaofeng Zeng, Shaohui Zong

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2024.113684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yanbin Feng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China; De…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Bone Neoplasms, Osteoclasts, Apoptosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Guangxi Medical University, Specific Research Project of Guangxi for Research Bases and Talents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer, as one of the most prevalent malignant tumors in men, seriously affects the prognosis and survival of patients due to its extremely high rate of bone metastasis. This study investigated the effect of Polyphyllin VI (PPVI) on metastatic bone disease for the first time in prostate cancer, focusing on its impact on osteoclast and tumor cell. In vitro studies utilized TRAP staining, ghost pen cyclic peptide staining, and bone resorption assays to evaluate the differentiation and function of receptor activator of nuclear factor-κB ligand (RANKL) induced and RM-1 conditional medium (CM) induced osteoclasts. The colony formation assay, wound healing assay, and Transwell assay were employed to analyze tumor cell proliferation, migration, and invasion in vitro. Flow cytometry was used to detect the cycling and apoptosis of tumor cells in vitro. Western Blot and PCR assays were conducted to assess the expression of genes. In vivo, micro-CT, hematoxylin-eosin staining, and immunohistochemical staining evaluated the impact of PPVI on bone destruction and tumor growth in a mouse model of tumor tibial metastasis. The study results indicated that PPVI effectively inhibited osteoclast differentiation, suppresses tumor cell proliferation, migration, and invasion in vitro, and induces apoptosis and G2/M phase arrest. In vivo, PPVI not only inhibits the growth of metastatic tumors but also mitigates the resulting bone destruction. These results suggest that PPVI holds significant potential as an alternative treatment for prostate cancer with bone metastasis, providing insights into its molecular mechanisms and therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBone NeoplasmsOsteoclastsApoptosisCell ProliferationCell MovementMaleAnimalsHumansMiceCell Line, TumorCell DifferentiationRANK LigandSaponins

Stichwörter der Autor:innen

ApoptosisBone metastasesOsteoclastPolyphyllin VIProstate cancer

Substanzen

RANK LigandSaponins

Autor:innen und Institutionen

  • Department of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China; Department of Orthopaedics, Qilu Hospital of Shandong University, Shando…
  • Department of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China.
  • Department of Orthopaedics, Qilu Hospital of Shandong University, Shandong University Centre for Orthopaedics, Jinan, Shandong, China.
  • Department of Nutrition and Food Hygiene, College of Public Hygiene of Guangxi Medical University, Nanning, Guangxi, China. Electronic address: zenggaofeng@gxmu.edu.cn.
  • Department of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China. Electronic address: zongshaohui@gxmu.edu.cn.

Förderung

  • Guangxi Medical University
  • Specific Research Project of Guangxi for Research Bases and Talents

Zitieren

APA

Feng, Y., Mo, Y., Zhang, Y., Teng, Y., Xi, D., Zhou, J., Zeng, G., & Zong, S. (2025). Polyphyllin VI: A promising treatment for prostate cancer bone metastasis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113684

Vancouver

Feng Y, Mo Y, Zhang Y, Teng Y, Xi D, Zhou J, et al. Polyphyllin VI: A promising treatment for prostate cancer bone metastasis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113684

BibTeX
@article{Feng2025,
  author = {Feng, Yanbin and Mo, Yaomin and Zhang, Yang and Teng, Yilin and Xi, Deshuang and Zhou, Junhong and Zeng, Gaofeng and Zong, Shaohui},
  title = {Polyphyllin VI: A promising treatment for prostate cancer bone metastasis},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2024.113684}
}
Kostenlos starten →